Heart failure and comorbidities: Renal failure, diabetes, atrial fibrillation, and inflammation

European Heart Journal

Volumn 36, Issue 23, 2015, Pages 1415-1417

  Lüscher, Thomas F ^a  

^a University Hospital of Zurich   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT ACTIVITY; ATRIAL FIBRILLATION; CARDIAC PATIENT; CARDIORENAL SYNDROME; CARDIOVASCULAR MORTALITY; CENTRAL SLEEP APNEA SYNDROME; COMORBIDITY; DIABETES MELLITUS; GENETIC VARIABILITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HOSPITALIZATION; HUMAN; INFLAMMATION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PERFUSION; MENDELIAN RANDOMIZATION ANALYSIS; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDERED BREATHING; VENOUS CONGESTION; COMPLICATION; DIABETIC ANGIOPATHY; MYOCARDITIS;

ATRIAL FIBRILLATION; CARDIO-RENAL SYNDROME; DIABETIC ANGIOPATHIES; HEART FAILURE; HUMANS; MYOCARDITIS;

EID: 84942415910     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv156     Document Type: Short Survey

References (24)

1. Amaral N, Varkey S, Demir O, Sharma P, Varsani N, Kelshikir M, Norrington K, Turner HK, Barakat MF, Okonko DO, Amaral N, Varkey S, Demir O, Sharma P, Varsani N, Kelshikir M, Norrington K, Turner HK, BarakatMF, Okonko DO. The cardiorenal volume index: A simple biochemical algorithm for the differentiation, assessment, and risk stratification of patients hospitalized for heart failure. Eur Heart J 2013; 34(Suppl 1):P5060.
2. Moukarzel JA, Klin P, Zambrano C, DuczynskiMP, Ochoa JP, Bilbao A, Klein F. Clinical relevance of dynamic changes in renal function in patients admitted for acute heart failure. Eur Heart J 2013;34(Suppl 1):P2733.
3. Damman K, Testani JM. The kidney in heart failure: An update. Eur Heart J 2015;36: 1437-1444.
4. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J 2014;35:455-469.
5. Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T, Campia U, Ambrosy A, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade M. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J 2011;32:2563-2572.
6. Sharma S, Merghani A, Mont L. Exercise and the heart: The good, the bad, and the ugly. Eur Heart J 2015;36:1445-1453.
7. Semsarian C, Ingles J, Wilde AAM. Sudden cardiac death in the young: The molecular autopsy and a practical approach to surviving relatives. Eur Heart J 2015;36: 1290-1296.
8. Zaidi A, Ghani S, Sheikh N, Gati S, Bastiaenen R, Madden B, Papadakis M, Raju H, Reed M, Sharma R, Behr ER, Sharma S. Clinical significance of electrocardiographic right ventricular hypertrophy in athletes: comparison with arrhythmogenic right ventricular cardiomyopathy and pulmonary hypertension. Eur Heart J 2013;34: 3649-56.
9. Pasquie J-L, Hedon C, Alfalasi O, Thomann S, Massin F, Cransac F, Cung TT, Davy JM. Endurance sports precipitate phenotypic expression of arrhythmogenic right ventricular cardiomyopathy (ARVC) in asymptomatic PKP2-mutation carriers. Eur Heart J 2013;34(Suppl 1): P1901.
10. Thiene G. The research venture in arrhythmogenic right ventricular cardiomyopathy: A paradigm of translational medicine. Eur Heart J 2015;36:837-848.
11. Khayat R, Jarjoura D, Porter K, Sow A, Wannemacher J, Dohar R, Pleister A, Abraham WT. Sleep-disordered breathing and post-discharge mortality in patients with acute heart failure. Eur Heart J 2015;36:1463-1469.
12. Floras JS, Bradley TD. Sleep apnoea in acute heart failure: fluid in flux. Eur Heart J 2015;36:1428-1430.
13. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 2013;34:2436-2443.
14. Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 2013;34:2444-2452.
15. Sud M, Wang X, Austin PC, Lipscombe LL, Newton GE, Tu JV, Vasan RS, Lee DS. Presentation blood glucose and death, hospitalization, and future diabetes risk in patients with acute heart failure syndromes. Eur Heart J 2015;36:924-931.
16. Ross S, Gerstein HC, Eikelboom J, Anand SS, Yusuf S, Pare G. Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. Eur Heart J 2015;36:1454-1462.
17. Bhatt DL. Yes, hyperglycaemia is indeed a modifiable cardiac risk factor: so says Mendel. Eur Heart J 2015;36:1424-1427.
18. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, Mahaffey KW, Fox KA, Califf RM, Piccini JP. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: Results from the ROCKET-AF Trial. Eur Heart J 2015;36:288-296.
19. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, Crijns HJ, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP, Boriani G. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2014;35: 3365-3376.
20. O'Donoghue ML, Ruff CT, Giugliano RP, Murphy SA, Grip LT, Mercuri MF, Rutman H, Shi M, Kania G, Cermak O, Braunwald E, Antman EM. Edoxaban vs. warfarin in vitamin K antagonist-experienced and naive patients with atrial fibrillation. Eur Heart J 2015;36:1470-1477.
21. Pokorney SD, Granger CB. Should patients on vitamin K antagonists be treated differently? Eur Heart J 2015;36:1431-1433.
22. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636-2648.
23. Leuschner F, Courties G, Dutta P, Mortensen LJ, Gorbatov R, Sena B, Novobrantseva TI, Borodovsky A, Fitzgerald K, Koteliansky V, Iwamoto Y, Bohlender M, Meyer S, Lasitschka F, Meder B, Katus HA, Lin C, Libby P, Swirski FK, Anderson DG, Weissleder R, Nahrendorf M. Silencing of CCR2 in myocarditis. Eur Heart J 2015;36:1478-1488.
24. Cooper LT Jr, Fairweather D. Nano-scale treatment for a macro-scale disease: nanoparticle-delivered siRNA silences CCR2 and treats myocarditis. Eur Heart J 2015;36:1434-1436.